Analyzing MDxHealth (NASDAQ:MDXH) and Mitesco (OTCMKTS:MITI)

MDxHealth (NASDAQ:MDXH) and Mitesco (OTCMKTS:MITI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares MDxHealth and Mitesco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-41.02%	-492.11%	-23.00%
Mitesco	1,456.66%	N/A	-1,202.21%

Valuation and Earnings

This table compares MDxHealth and Mitesco”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$90.05 million	1.04	-$38.07 million	($1.15)	-1.72
Mitesco	$40,000.00	92.05	-$2.51 million	N/A	N/A

Mitesco has lower revenue, but higher earnings than MDxHealth.

Institutional and Insider Ownership

0.0% of Mitesco shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 4.9% of Mitesco shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for MDxHealth and Mitesco, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	0	0	2	0	3.00
Mitesco	0	0	0	0	0.00

MDxHealth presently has a consensus price target of $6.50, indicating a potential upside of 228.28%. Given MDxHealth’s stronger consensus rating and higher possible upside, research analysts clearly believe MDxHealth is more favorable than Mitesco.

Risk & Volatility

MDxHealth has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Mitesco has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.

Summary

Mitesco beats MDxHealth on 7 of the 12 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Mitesco

Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.